SRR17866837
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 39.3
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.480
- PANCREAS_BETA_CELLS+0.330
- FATTY_ACID_METABOLISM+0.290
- MITOTIC_SPINDLE+0.280
- PEROXISOME+0.270
- GLYCOLYSIS+0.250
- OXIDATIVE_PHOSPHORYLATION+0.230
- BILE_ACID_METABOLISM+0.210
- ANDROGEN_RESPONSE+0.160
- UNFOLDED_PROTEIN_RESPONSE+0.150
Top 10 suppressed
- MYC_TARGETS_V2-0.410
- ALLOGRAFT_REJECTION-0.380
- IL6_JAK_STAT3_SIGNALING-0.380
- INTERFERON_GAMMA_RESPONSE-0.380
- ANGIOGENESIS-0.370
- HEDGEHOG_SIGNALING-0.370
- MYOGENESIS-0.370
- INTERFERON_ALPHA_RESPONSE-0.360
- TNFA_SIGNALING_VIA_NFKB-0.350
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.340
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR12202430 | — | — | 0.872 |
| 2 | TCGA-BB-4227-01A-01R-1873-07 | — | — | 0.833 |
| 3 | 84a15687-a977-43a1-b2b7-099ecdf21b2c | — | — | 0.818 |
| 4 | R150 | — | — | 0.808 |
| 5 | R391 | — | — | 0.807 |
| 6 | SJEPD031010_D1.RNA-Seq | EPN | EPN Tumor | 0.799 |
| 7 | DRR168601 | — | — | 0.781 |
| 8 | f8676f25-4b49-44b3-b953-c457c3be5a3b | — | — | 0.774 |
| 9 | TCGA-E9-A1N3-01A-12R-A157-07 | — | B | 0.772 |
| 10 | R288 | — | — | 0.770 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.480 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.330 | Cobimetinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.290 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.280 | Inavolisib | — uncovered |
| PEROXISOME | 0.270 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.250 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.230 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.210 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.160 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.150 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.140 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.140 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.130 | Temsirolimus | — uncovered |
| UV_RESPONSE_DN | 0.100 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.090 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.090 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.060 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.030 | Inavolisib | — uncovered |
| HYPOXIA | 0.030 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.030 | Inavolisib | — uncovered |